KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Tax Provisions (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Tax Provisions for 10 consecutive years, with $40.7 million as the latest value for Q4 2025.

  • Quarterly Tax Provisions fell 1.12% to $40.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $149.9 million through Dec 2025, up 32.62% year-over-year, with the annual reading at $150.0 million for FY2025, 32.68% up from the prior year.
  • Tax Provisions for Q4 2025 was $40.7 million at Halozyme Therapeutics, down from $43.7 million in the prior quarter.
  • The five-year high for Tax Provisions was $43.7 million in Q3 2025, with the low at -$142.5 million in Q3 2021.
  • Average Tax Provisions over 5 years is $11.1 million, with a median of $17.1 million recorded in 2023.
  • The sharpest move saw Tax Provisions crashed 226260.32% in 2021, then skyrocketed 12531.03% in 2022.
  • Over 5 years, Tax Provisions stood at -$12.0 million in 2021, then soared by 209.44% to $13.1 million in 2022, then increased by 20.61% to $15.8 million in 2023, then soared by 160.99% to $41.2 million in 2024, then dropped by 1.12% to $40.7 million in 2025.
  • According to Business Quant data, Tax Provisions over the past three periods came in at $40.7 million, $43.7 million, and $39.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.